Argenica Therapeutics Limited (AGN.AX)
AUD 0.62
(-3.13%)
AUD 0.62
(-3.13%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 16.37 Million AUD | 71.66% |
| 2023 | 9.54 Million AUD | 5.5% |
| 2022 | 9.04 Million AUD | 24.35% |
| 2021 | 7.27 Million AUD | 1825.67% |
| 2020 | 377.66 Thousand AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 16.37 Million AUD | 89.98% |
| 2024 Q4 | 16.37 Million AUD | 0.0% |
| 2024 Q1 | 8.62 Million AUD | -4.68% |
| 2024 FY | 16.37 Million AUD | 71.66% |
| 2024 Q2 | 8.62 Million AUD | 0.0% |
| 2023 Q3 | 9.54 Million AUD | 15.28% |
| 2023 FY | 9.54 Million AUD | 5.5% |
| 2023 Q2 | 8.27 Million AUD | 0.0% |
| 2023 Q1 | 8.27 Million AUD | -8.48% |
| 2023 Q4 | 9.04 Million AUD | -5.21% |
| 2022 Q4 | 9.04 Million AUD | 0.0% |
| 2022 Q1 | 5.39 Million AUD | -25.85% |
| 2022 Q3 | 9.04 Million AUD | 67.69% |
| 2022 FY | 9.04 Million AUD | 24.35% |
| 2022 Q2 | 5.39 Million AUD | 0.0% |
| 2021 Q3 | 7.27 Million AUD | 468.8% |
| 2021 FY | 7.27 Million AUD | 1825.67% |
| 2021 Q4 | 7.27 Million AUD | 0.0% |
| 2021 Q2 | 1.27 Million AUD | 0.0% |
| 2021 Q1 | 1.27 Million AUD | 238.55% |
| 2020 Q4 | 377.66 Thousand AUD | 0.0% |
| 2020 FY | 377.66 Thousand AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 25.55 Million AUD | 35.905% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -879.858% |
| Zelira Therapeutics Limited | 5.18 Million AUD | -215.961% |
| Biome Australia Limited | 8.27 Million AUD | -97.873% |
| Patrys Limited | 4.16 Million AUD | -293.542% |
| Orthocell Limited | 26.61 Million AUD | 38.465% |
| Imugene Limited | 151.39 Million AUD | 89.182% |
| Noxopharm Limited | 6.78 Million AUD | -141.423% |
| PYC Therapeutics Limited | 91.23 Million AUD | 82.05% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | -7.231% |
| Prescient Therapeutics Limited | 20.39 Million AUD | 19.69% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | -50.597% |
| Cynata Therapeutics Limited | 8.38 Million AUD | -95.243% |
| CSL Limited | 56.93 Billion AUD | 99.971% |
| Arovella Therapeutics Limited | 13.28 Million AUD | -23.281% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -418.344% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 92.914% |
| Starpharma Holdings Limited | 36.81 Million AUD | 55.513% |
| Nanollose Limited | 241.95 Thousand AUD | -6668.955% |
| Memphasys Limited | 12.43 Million AUD | -31.757% |
| Invex Therapeutics Ltd | 6.12 Million AUD | -167.605% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -201.287% |
| Amplia Therapeutics Limited | 14.84 Million AUD | -10.323% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | 85.438% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -538.633% |
| Race Oncology Limited | 20.22 Million AUD | 19.038% |
| Nyrada Inc. | 5.9 Million AUD | -177.244% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 95.888% |
| Dimerix Limited | 32.07 Million AUD | 48.945% |
| PharmAust Limited | 11.12 Million AUD | -47.216% |
| Immutep Limited | 147.44 Million AUD | 88.893% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 89.408% |
| Alterity Therapeutics Limited | 19.22 Million AUD | 14.806% |
| BTC Health Limited | 5.14 Million AUD | -218.084% |
| Acrux Limited | 8.96 Million AUD | -82.724% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | 93.395% |
| Biotron Limited | 493.47 Thousand AUD | -3218.815% |
| Tissue Repair Ltd | 19.38 Million AUD | 15.534% |
| AdAlta Limited | 5.57 Million AUD | -193.873% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | 77.265% |
| Hexima Limited | 2.26 Million AUD | -621.795% |
| AnteoTech Limited | 9.38 Million AUD | -74.579% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 40.207% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | -157.12% |
| Avecho Biotechnology Limited | 7.31 Million AUD | -123.758% |
| Actinogen Medical Limited | 21.31 Million AUD | 23.153% |
| Immuron Limited | 15.54 Million AUD | -5.322% |